Pharmacokinetics of ganciclovir and valganciclovir in the adult horse

Journal of Veterinary Pharmacology and Therapeutics

Volumn 36, Issue 5, 2013, Pages 441-449

  Carmichael, R J ^a   Whitfield, C ^a   Maxwell, L K ^a  

^a OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; VALGANCICLOVIR;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG POTENCY; FEMALE; HERPES SIMPLEX; HORSE; MAINTENANCE DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EQUID HERPESVIRUS 1; EQUIDAE; HERPES; HUMAN HERPESVIRUS 1;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; FEMALE; GANCICLOVIR; HORSES; INJECTIONS, INTRAVENOUS; MALE;

EID: 84883655404     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/jvp.12029     Document Type: Article

References (39)

1. Acosta, E.P., Brundage, R.C., King, J.R., Sanchez, P.J., Sood, S., Agrawal, V., Homans, J., Jacobs, R.F., Lang, D., Romero, J.R., Griffin, J., Cloud, G., Whitley, R. & Kimberlin, D.W. (2007) Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. Clinical Pharmacology and Therapeutics, 81, 867-872.
2. Bentz, B.G., Maxwell, L.K., Erkert, R.S., Royer, C.M., Davis, M.S., MacAllister, C.G. & Clarke, C.R. (2006) Pharmacokinetics of acyclovir after single intravenous and oral administration to adult horses. Journal of Veterinary Internal Medicine, 20, 589-594.
3. Chu, F., Kiang, C.H., Sung, M.L., Huang, B., Reeve, R.L. & Tarnowski, T. (1999) A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. Journal of Pharmaceutical and Biomedical Analysis, 21, 657-667.
4. Edington, N., Bridges, C.G. & Patel, J.R. (1986) Endothelial cell infection and thrombosis in paralysis caused by equid herpesvirus-1: equine stroke. Archives of Virology, 90, 111-124.
5. Fletcher, C., Sawchuk, R., Chinnock, B., de Miranda, P. & Balfour, H.H. Jr (1986) Human pharmacokinetics of the antiviral drug DHPG. Clinical Pharmacology and Therapeutics, 40, 281-286.
6. Garré, B., Shebany, K., Gryspeerdt, A., Baert, K., van der Meulen, K., Nauwynck, H., Deprez, P., De Backer, P. & Croubels, S. (2007a) Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. Antimicrobial Agents and Chemotherapy, 51, 4308-4314.
7. Garré, B., van der Meulen, K., Nugent, J., Neyts, J., Croubels, S., De Backer, P. & Nauwynck, H. (2007b) In vitro susceptibility of six isolates of equine herpesvirus 1 to acyclovir, ganciclovir, cidofovir, adefovir, PMEDAP and foscarnet. Veterinary Microbiology, 122, 43-51.
8. Garré, B., Baert, K., Nauwynck, H., Deprez, P., De Backer, P. & Croubels, S. (2009a) Multiple oral dosing of valacyclovir in horses and ponies. Journal of Veterinary Pharmacology and Therapeutics, 32, 207-212.
9. Garré, B., Gryspeerdt, A., Croubels, S., De Backer, P. & Nauwynck, H. (2009b) Evaluation of orally administered valacyclovir in experimentally EHV1-infected ponies. Veterinary Microbiology, 135, 214-221.
10. Goodman, L.B., Loregian, A., Perkins, G.A., Nugent, J., Buckles, E.L., Mercorelli, B., Kydd, J.H., Palu, G., Smith, K.C., Osterrieder, N. & Davis-Poynter, N. (2007) A point mutation in a herpesvirus polymerase determines neuropathogenicity. PLoS Pathogens, 3, e160.
11. Hedaya, M.A. & Sawchuk, R.J. (1990) A sensitive and specific liquid-chromatographic assay for determination of ganciclovir in plasma and urine and its application to pharmacokinetic studies in the rabbit. Pharmaceutical Research, 7, 1113-1118.
12. Henkin, C.C., Griener, J.C. & Ten Eick, A.P. (2003) Stability of valganciclovir in extemporaneously compounded liquid formulations. American Journal of Health-System Pharmacy, 60, 687-690.
13. Jacobsen, T. & Sifontis, N. (2010) Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection. American Journal of Health-System Pharmacy, 67, 1417-1425.
14. Jacobson, M.A., de Miranda, P., Cederberg, D.M., Burnette, T., Cobb, E., Brodie, H.R. & Mills, J. (1987) Human pharmacokinetics and tolerance of oral ganciclovir. Antimicrobial Agents and Chemotherapy, 31, 1251-1254.
15. Krasny, H.C., de Miranda, P., Blum, M.R. & Elion, G.B. (1981) Pharmacokinetics and bioavailability of acyclovir in the dog. Journal of Pharmacology and Experimental Therapeutics, 216, 281-288.
16. Kydd, J.H., Townsend, H.G. & Hannant, D. (2006) The equine immune response to equine herpesvirus-1: the virus and its vaccines. Veterinary Immunology and Immunopathology, 111, 15-30.
17. Lunn, D.P., Davis-Poynter, N., Flaminio, M.J., Horohov, D.W., Osterrieder, K., Pusterla, N. & Townsend, H.G. (2009) Equine herpesvirus-1 consensus statement. Journal of Veterinary Internal Medicine, 23, 450-461.
18. Martin-Jimenez, T., Papich, M.G. & Riviere, J.E. (1998) Population pharmacokinetics of gentamicin in horses. American Journal of Veterinary Research, 59, 1589-1598.
19. Maxwell, L.K., Bentz, B.G., Bourne, D.W. & Erkert, R.S. (2008a) Pharmacokinetics of valacyclovir in the adult horse. Journal of Veterinary Pharmacology and Therapeutics, 31, 312-320.
20. Maxwell, L.K., Bentz, B.G., Gilliam, L.L., Ritchey, J.W., Eberle, R.W., Holbrook, T.C., McFarlane, D., Rezabek, G.B., MacAllister, C.G., Goad, C.L. & Allen, G.P. (2008b) Efficacy of valacyclovir against clinical disease after EHV-1 challenge in aged mares. In Proceedings of the 54th Annual Convention of the American Association of Equine Practitioners, San Diego, California, USA, 6-10 December 2008. Ed. Werner, H.W., pp. 198-199. American Association of Equine Practitioners (AAEP), Lexington.
21. Nicolau, D.P., Freeman, C.D., Belliveau, P.P., Nightingale, C.H., Ross, J.W. & Quintiliani, R. (1995) Experience with a once-daily aminoglycoside program administered to 2, 184 adult patients. Antimicrobial Agents and Chemotherapy, 39, 650-655.
22. Nugent, J., Birch-Machin, I., Smith, K.C., Mumford, J.A., Swann, Z., Newton, J.R., Bowden, R.J., Allen, G.P. & Davis-Poynter, N. (2006) Analysis of equid herpesvirus 1 strain variation reveals a point mutation of the DNA polymerase strongly associated with neuropathogenic versus nonneuropathogenic disease outbreaks. Journal of Virology, 80, 4047-4060.
23. Perkins, G.A., Goodman, L.B., Tsujimura, K., Van de Walle, G.R., Kim, S.G., Dubovi, E.J. & Osterrieder, N. (2009) Investigation of the prevalence of neurologic equine herpes virus type 1 (EHV-1) in a 23-year retrospective analysis (1984-2007). Veterinary Microbiology, 139, 375-378.
24. Pescovitz, M.D. (1999) Oral ganciclovir and pharmacokinetics of valganciclovir in liver transplant recipients. Transplant Infectious Disease, 1 (Suppl. 1), 31-34.
25. Pollina, G.F., Zagotto, G., Maritan, P., Iacopetti, I. & Busetto, R. (2012) Pharmacokinetics of gallium nitrate after oral administration in adult horses - pilot study. Journal of Veterinary Pharmacology and Therapeutics, 35, 489-494.
26. Saxegaard, F. (1966) Isolation and identification of equine rhinopneumonitis virus (equine abortion virus) from cases of abortion and paralysis. Nordisk Veterinaermedicin, 18, 504-512.
27. Serabe, B.M., Murry, D.J., Dauser, R., Nuchtern, J., Durfee, J., McGuffey, L., Berg, S. & Blaney, S.M. (1999) Plasma and CSF pharmacokinetics of ganciclovir in nonhuman primates. Cancer Chemotherapy and Pharmacology, 43, 415-418.
28. Sommadossi, J.P., Bevan, R., Ling, T., Lee, F., Mastre, B., Chaplin, M.D., Nerenberg, C., Koretz, S. & Buhles, W.C. Jr (1988) Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. Reviews of Infectious Diseases, 10 (Suppl. 3), S507-S514.
29. Stefanidis, D. & Brandl, M. (2005) Reactivity of valganciclovir in aqueous solution. Drug Development and Industrial Pharmacy, 31, 879-884.
30. Thron, C.D. (1974) Linearity and superposition in pharmacokinetics. Pharmacological Reviews, 26, 3-31.
31. Tod, M., Lokiec, F., Bidault, R., De Bony, F., Petitjean, O. & Aujard, Y. (2001) Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis. Antimicrobial Agents and Chemotherapy, 45, 150-157.
32. Tsujimura, K., Yamada, M., Nagata, S., Yamanaka, T., Nemoto, M., Kondo, T., Kurosawa, M. & Matsumura, T. (2010) Pharmacokinetics of penciclovir after oral administration of its prodrug famciclovir to horses. Journal of Veterinary Medical Science, 72, 357-361.
33. Wang, W. & Ouyang, S.P. (1998) The formulation of the principle of superposition in the presence of non-compliance and its applications in multiple dose pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics, 26, 457-469.
34. Wilkins, P.A., Henninger, R., Reed, S.M., Piero, F.D. & del Piero, F. (2003) Acyclovir as Treatment for EHV-1 Myeloencephalopathy. Proceedings of the 49th Annual Convention of the American Association of Equine Practitioners, New Orleans, Louisiana, USA, 21-25 November 2003, pp. 394-396. American Association of Equine Practitioners (AAEP), Lexington.
35. Wilkins, P.A., Papich, M. & Sweeney, R.W. (2005) Pharmacokinetics of acyclovir in adult horses. Journal of Veterinary Emergency and Critical Care, 15, 174-178.
36. Wilson, K.E., Wilcke, J.R., Crisman, M.V., Ward, D.L., McKenzie, H.C. & Scarratt, W.K. (2009) Comparison of serum iohexol clearance and plasma creatinine clearance in clinically normal horses. American Journal of Veterinary Research, 70, 1545-1550.
37. Wiltshire, H., Hirankarn, S., Farrell, C., Paya, C., Pescovitz, M.D., Humar, A., Dominguez, E., Washburn, K., Blumberg, E., Alexander, B., Freeman, R. & Heaton, N. (2005) Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clinical Pharmacokinetics, 44, 495-507.
38. Winston, D.J., Baden, L.R., Gabriel, D.A., Emmanouilides, C., Shaw, L.M., Lange, W.R. & Ratanatharathorn, V. (2006) Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. Biology of Blood and Marrow Transplantation, 12, 635-640.
39. Zhao, W., Baudouin, V., Zhang, D., Deschenes, G., Le Guellec, C. & Jacqz-Aigrain, E. (2009) Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients. Clinical Pharmacokinetics, 48, 321-328.